BPDCN
MCID: BLS007
MIFTS: 48

Blastic Plasmacytoid Dendritic Cell (BPDCN)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Blastic Plasmacytoid Dendritic Cell

MalaCards integrated aliases for Blastic Plasmacytoid Dendritic Cell:

Name: Blastic Plasmacytoid Dendritic Cell 54
Blastic Plasmacytoid Dendritic Cell Neoplasm 54 60 74
Lymphoblastoid Variant of Nk-Cell Lymphoma 54 60
Cd4+/cd56+ Hematodermic Neoplasm 54 60
Monomorphic Nk-Cell Lymphoma 54 60
Blastic Nk-Cell Lymphoma 54 60
Bpdcn 54 60

Characteristics:

Orphanet epidemiological data:

60
cd4+/cd56+ hematodermic neoplasm
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Elderly; Age of death: elderly;

Classifications:



External Ids:

ICD10 34 C86.4
ICD10 via Orphanet 35 C86.4
Orphanet 60 ORPHA86870
UMLS 74 C1301363

Summaries for Blastic Plasmacytoid Dendritic Cell

MalaCards based summary : Blastic Plasmacytoid Dendritic Cell, also known as blastic plasmacytoid dendritic cell neoplasm, is related to leukemia, acute myeloid and b-cell lymphomas. An important gene associated with Blastic Plasmacytoid Dendritic Cell is TET2 (Tet Methylcytosine Dioxygenase 2), and among its related pathways/superpathways are PI3K-Akt signaling pathway and NF-kappaB Signaling. The drugs Trastuzumab and Adenosine have been mentioned in the context of this disorder. Affiliated tissues include nk cells, myeloid and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Blastic Plasmacytoid Dendritic Cell

Diseases related to Blastic Plasmacytoid Dendritic Cell via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute myeloid 30.1 IL3RA MYB MYC NCAM1 NPM1 TET2
2 b-cell lymphomas 29.6 CDKN1B CDKN2A MYC TCL1A
3 dendritic cell tumor 11.3
4 leukemia 10.8
5 myeloid leukemia 10.6
6 chronic myelomonocytic leukemia 10.4
7 lymphoma 10.4
8 pdgfrb-associated chronic eosinophilic leukemia 10.4
9 ovarian serous adenofibroma 10.3 NCAM1 NR3C1
10 leukemia, acute monocytic 10.3
11 myelodysplastic syndrome 10.3
12 hematopoietic stem cell transplantation 10.3
13 monocytic leukemia 10.3
14 acute basophilic leukemia 10.3 IL3RA MYB
15 primary cutaneous diffuse large b-cell lymphoma, leg type 10.3 CDKN2A MYD88
16 localized osteosarcoma 10.2 CDKN2A CLEC4C
17 protoporphyria, erythropoietic, 1 10.1
18 retinoblastoma 10.1
19 anemia, autoimmune hemolytic 10.1
20 rheumatic fever-related antigen 10.1
21 xanthomatosis 10.1
22 basal cell carcinoma 1 10.1
23 acute leukemia 10.1
24 hemolytic anemia 10.1
25 post-transplant lymphoproliferative disease 10.1
26 cutaneous lupus erythematosus 10.1
27 sarcoma 10.1
28 rheumatic fever 10.1
29 melanoma 10.1
30 basal cell carcinoma 10.1
31 purpura 10.1
32 polyradiculopathy 10.1
33 mucormycosis 10.1
34 myeloid sarcoma 10.1
35 lupus erythematosus 10.1
36 macroglobulinemia 10.1
37 splenomegaly 10.1
38 diphtheria 10.1
39 peripheral t-cell lymphoma 10.0 NCAM1 TCL1A TET2
40 subcutaneous panniculitis-like t-cell lymphoma 10.0 MYC NCAM1
41 retinal cancer 9.9 CDKN1B CDKN2A MYC
42 ocular cancer 9.9 CDKN1B CDKN2A MYC
43 lymphatic system cancer 9.9 MYC NCAM1 NPM1
44 nervous system cancer 9.9 CDKN1B CDKN2A MYC
45 t-cell prolymphocytic leukemia 9.8 CDKN1B MYC TCL1A
46 small cell cancer of the lung 9.8 CDKN2A MYC NCAM1
47 megaesophagus 9.8 CDKN2A MYC
48 mantle cell lymphoma 9.7 CDKN1B CDKN2A MYC
49 precursor t-cell acute lymphoblastic leukemia 9.6 CDKN2A MYB MYC TCL1A
50 lymphoma, non-hodgkin, familial 9.5 CDKN1B MYC NPM1 TCL1A

Graphical network of the top 20 diseases related to Blastic Plasmacytoid Dendritic Cell:



Diseases related to Blastic Plasmacytoid Dendritic Cell

Symptoms & Phenotypes for Blastic Plasmacytoid Dendritic Cell

GenomeRNAi Phenotypes related to Blastic Plasmacytoid Dendritic Cell according to GeneCards Suite gene sharing:

27 (show all 24)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.83 MYB
2 Increased shRNA abundance (Z-score > 2) GR00366-A-101 9.83 TCF4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.83 BRD4 TCF4
4 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.83 MYB
5 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.83 MYB
6 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.83 BRD4 IL3RA MYB TCF4
7 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.83 IL3RA
8 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.83 BRD4
9 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.83 MYB TCF4
10 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.83 MYB
11 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.83 MYB
12 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.83 MYB
13 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.83 MYB TCF4
14 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.83 IL3RA
15 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.83 TCF4
16 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.83 BRD4 TCF4
17 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.83 IL3RA TCF4
18 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.83 TCF4
19 Increased shRNA abundance (Z-score > 2) GR00366-A-65 9.83 MYB
20 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.83 MYB
21 Increased shRNA abundance (Z-score > 2) GR00366-A-76 9.83 TCF4
22 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.83 IL3RA
23 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.83 MYB
24 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.83 BRD4

MGI Mouse Phenotypes related to Blastic Plasmacytoid Dendritic Cell:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.27 CD4 CDKN1B CDKN2A MYB MYC MYD88
2 hematopoietic system MP:0005397 10.18 CD4 CDKN1B CDKN2A IL3RA MYB MYC
3 cardiovascular system MP:0005385 10.13 CDKN1B CDKN2A MYB MYC MYD88 NPM1
4 immune system MP:0005387 10.13 CD4 CDKN1B CDKN2A IL3RA MYB MYC
5 endocrine/exocrine gland MP:0005379 10.06 CD4 CDKN1B CDKN2A MYB MYC MYD88
6 digestive/alimentary MP:0005381 10.03 CD4 CDKN1B CDKN2A MYC MYD88 NR3C1
7 mortality/aging MP:0010768 9.97 CD4 CDKN1B CDKN2A MYB MYC MYD88
8 liver/biliary system MP:0005370 9.86 CDKN1B CDKN2A MYB MYC NPM1 NR3C1
9 neoplasm MP:0002006 9.43 CDKN1B CDKN2A MYC MYD88 NPM1 TET2
10 no phenotypic analysis MP:0003012 9.28 CD4 CDKN1B CDKN2A CLEC4C MYB MYC

Drugs & Therapeutics for Blastic Plasmacytoid Dendritic Cell

Drugs for Blastic Plasmacytoid Dendritic Cell (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 65)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
2
Adenosine Approved, Investigational Phase 2 58-61-7 60961
3
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
4
Idarubicin Approved Phase 2 58957-92-9 42890
5
leucovorin Approved Phase 2 58-05-9 6006 143
6
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
7
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
8
nivolumab Approved Phase 2 946414-94-4
9
Vidarabine Approved, Investigational Phase 2,Phase 1,Not Applicable 24356-66-9 21704 32326
10
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
11
Fludarabine Approved Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
12
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492 6473866
13
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 6055-19-2, 50-18-0 2907
14
Mycophenolic acid Approved Phase 2,Not Applicable 24280-93-1 446541
15
Busulfan Approved, Investigational Phase 2 55-98-1 2478
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
17 Lorvotuzumab mertansine Investigational Phase 2 1008106-64-6
18
Emodepside Investigational, Vet_approved Phase 2 155030-63-0
19 Antineoplastic Agents, Immunological Phase 2
20 Antimitotic Agents Phase 2
21 Maytansine Phase 2
22 Antineoplastic Agents, Phytogenic Phase 2
23 Ado-trastuzumab emtansine Phase 2
24 glucocorticoids Phase 2
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
26 Antirheumatic Agents Phase 2,Phase 1,Not Applicable
27 Folic Acid Antagonists Phase 2
28 Gastrointestinal Agents Phase 2
29 Dermatologic Agents Phase 2,Not Applicable
30 Antiemetics Phase 2
31 Vitamin B9 Phase 2
32 Folate Phase 2
33 Antibiotics, Antitubercular Phase 2,Not Applicable
34 Antimetabolites, Antineoplastic Phase 2,Phase 1,Not Applicable
35 Antineoplastic Agents, Hormonal Phase 2
36 Hormone Antagonists Phase 2
37 Immunologic Factors Phase 2,Phase 1,Not Applicable
38 Nucleic Acid Synthesis Inhibitors Phase 2
39 Topoisomerase Inhibitors Phase 2
40 Autonomic Agents Phase 2
41 BB 1101 Phase 2
42 Antimetabolites Phase 2,Phase 1,Not Applicable
43 Hormones Phase 2
44 Vitamin B Complex Phase 2
45 Immunosuppressive Agents Phase 2,Phase 1,Not Applicable
46 Peripheral Nervous System Agents Phase 2
47 Anti-Bacterial Agents Phase 2,Not Applicable
48 Anti-Inflammatory Agents Phase 2
49
asparaginase Phase 2
50 Antitubercular Agents Phase 2,Not Applicable

Interventional clinical trials:

(show all 19)
# Name Status NCT ID Phase Drugs
1 DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00397579 Phase 1, Phase 2 DT388IL3
2 An Open-label Phase II Study of Lorvotuzumab Mertansine Completed NCT02420873 Phase 2 Lorvotuzumab Mertansine (IMGN901)
3 Combination Chemotherapy in Patients With Newly Diagnosed BPDCN Recruiting NCT03599960 Phase 2 Chemotherapy
4 Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Recruiting NCT03075553 Phase 2
5 Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD Recruiting NCT02220985 Phase 2 Cyclophosphamide;Fludarabine Phosphate;Methotrexate;Mycophenolate Mofetil;Tacrolimus;Thiotepa
6 SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia Active, not recruiting NCT02113982 Phase 1, Phase 2 SL-401
7 Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Not yet recruiting NCT03739606 Phase 2
8 Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant Not yet recruiting NCT03779854 Phase 2 Thiotepa;Fludarabine;Cyclophosphamide;Busulfan;Tacrolimus;Methotrexate
9 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01231919 Phase 1 Akt inhibitor MK2206
10 Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Recruiting NCT03485547 Phase 1 Venetoclax
11 Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN Recruiting NCT03203369 Phase 1
12 Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Recruiting NCT02159495 Phase 1 cyclophosphamide;Fludarabine Phosphate
13 Study of IMGN632 in Patients With Relapse/Refractory AML, BPDCN, ALL, Other CD123+ Hem Malignancies Recruiting NCT03386513 Phase 1 IMGN632
14 HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant Recruiting NCT03326921 Phase 1 Fludarabine Phosphate
15 PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies Active, not recruiting NCT02730312 Phase 1
16 Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Not yet recruiting NCT03807063 Phase 1 Rimiducid
17 Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN) Completed NCT02859623
18 Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma Active, not recruiting NCT02652715 Not Applicable
19 Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies Active, not recruiting NCT00014235 Not Applicable fludarabine phosphate;cyclosporine;mycophenolate mofetil

Search NIH Clinical Center for Blastic Plasmacytoid Dendritic Cell

Genetic Tests for Blastic Plasmacytoid Dendritic Cell

Anatomical Context for Blastic Plasmacytoid Dendritic Cell

MalaCards organs/tissues related to Blastic Plasmacytoid Dendritic Cell:

42
Nk Cells, Myeloid, T Cells, Skin, Bone, Bone Marrow, Lung

Publications for Blastic Plasmacytoid Dendritic Cell

Articles related to Blastic Plasmacytoid Dendritic Cell:

(show top 50) (show all 265)
# Title Authors Year
1
Blastic plasmacytoid dendritic cell neoplasm with immunoblastoid morphology and MYC rearrangement and overexpression. ( 30482401 )
2019
2
Blastic plasmacytoid dendritic cell neoplasm with response to pralatrexate. ( 30652209 )
2019
3
Blastic Plasmacytoid Dendritic Cell Neoplasm; A Report of Three Cases. ( 30666080 )
2019
4
Clinical efficacy of bortezomib and lenalidomide in blastic plasmacytoid dendritic cell neoplasm. ( 30694364 )
2019
5
Blastic Plasmacytoid Dendritic Cell Neoplasm. ( 30715612 )
2019
6
Blastic plasmacytoid dendritic cell neoplasm with unusual extracutaneous manifestation: Two case reports and literature review. ( 30732162 )
2019
7
Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report. ( 30734052 )
2019
8
More on Blastic Plasmacytoid Dendritic-Cell Neoplasms. ( 30763185 )
2019
9
Chronic myelomonocytic leukaemia followed by blastic plasmacytoid dendritic cell neoplasm. ( 30784042 )
2019
10
More on Blastic Plasmacytoid Dendritic-Cell Neoplasms. ( 30785714 )
2019
11
More on Blastic Plasmacytoid Dendritic-Cell Neoplasms. ( 30785715 )
2019
12
Blastic Plasmacytoid Dendritic Cell Neoplasm with leukemic component ( 30819627 )
2019
13
Blastic plasmacytoid dendritic cell neoplasm: an early presentation. ( 30865410 )
2019
14
First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases. ( 29720227 )
2018
15
Benefit of electron beam therapy in combination with medium-dose systemic corticosteroid as a palliative treatment for elderly patients with blastic plasmacytoid dendritic cell neoplasm: case report and review of the literature. ( 29876950 )
2018
16
Blastic plasmacytoid dendritic cell neoplasm arising from clonal hematopoiesis. ( 29705980 )
2018
17
Clinicopathologic retrospective analysis of blastic plasmacytoid dendritic cell neoplasms. ( 29760611 )
2018
18
Detection of Minimal Bone Marrow involvement of Blastic Plasmacytoid Dendritic Cell Neoplastic Cells - CD303 immunostaining as a diagnostic tool. ( 29415975 )
2018
19
Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents. ( 29455234 )
2018
20
Immunophenotypic CD56 Variation Within a Single Patient With Blastic Plasmacytoid Dendritic Cell Neoplasm. ( 29490374 )
2018
21
Blastic plasmacytoid dendritic cell neoplasm: a rare case of gingival lesion with leukaemic presentation. ( 29735506 )
2018
22
Clonal evolution in the transition from cutaneous disease to acute leukaemia suggested by liquid biopsy in blastic plasmacytoid dendritic cell neoplasm. ( 29419438 )
2018
23
Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response. ( 29795241 )
2018
24
Blastic plasmacytoid dendritic cell neoplasm with centrocyte-like morphology clinically simulating a melanocytic nevus. ( 29293270 )
2018
25
Blastic plasmacytoid dendritic cell neoplasm. ( 29636962 )
2018
26
Report On Three Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. ( 29666036 )
2018
27
Atypical presentation of blastic plasmacytoid dendritic cell neoplasm: A potential diagnostic pitfall in nasal cavity. ( 29884520 )
2018
28
8q24/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms. ( 29407586 )
2018
29
Exploring the effect of chidamide on blastic plasmacytoid dendritic cell neoplasm: a case report and literature review. ( 29379294 )
2018
30
A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis. ( 29080220 )
2018
31
Blastic plasmacytoid dendritic cell neoplasm with unusual morphology, MYC rearrangement and TET2 and DNMT3A mutations. ( 29411884 )
2018
32
An Analysis of Blastic Plasmacytoid Dendritic Cell Neoplasm with Translocations Involving the MYC Locus Identifies t(6;8)(p21;q24) as a Recurrent Cytogenetic Abnormality. ( 29884995 )
2018
33
Skin lesions serve as clues to relapse of pediatric blastic plasmacytoid dendritic cell neoplasm. ( 29436012 )
2018
34
Incidental diagnosis of blastic plasmacytoid dendritic cell neoplasm in skin excision for basal cell carcinoma. ( 30094841 )
2018
35
The distinctive cytology and disease evolution of blastic plasmacytoid dendritic cell neoplasm. ( 30020546 )
2018
36
A Case of Blastic Plasmacytoid Dendritic Cell Neoplasm With Unusual Presentation. ( 30040070 )
2018
37
The advances in therapy of blastic plasmacytoid dendritic cell neoplasm. ( 30118336 )
2018
38
Blastic Plasmacytoid Dendritic Cell Neoplasm: Still an Enigma. ( 30127580 )
2018
39
Allogeneic Hematopoietic Cell Transplantation Is an Effective Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm in First Complete Remission: Systematic Review and Meta-analysis. ( 30145196 )
2018
40
Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. ( 30189324 )
2018
41
Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms. ( 30190511 )
2018
42
Genomic aberrations involving 12p/ETV6 are highly prevalent in blastic plasmacytoid dendritic cell neoplasms and might represent early clonal events. ( 30248580 )
2018
43
An unexpected diagnosis: leukaemic presentation of blastic plasmacytoid dendritic cell neoplasm with massive splenomegaly. ( 30274817 )
2018
44
Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell Neoplasm. ( 30304659 )
2018
45
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN-Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community. ( 30338458 )
2018
46
Blastic Plasmacytoid Dendritic Cell Neoplasm. ( 30350260 )
2018
47
Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target. ( 30381297 )
2018
48
Clinicopathological analysis of 46 cases with CD4+ and/or CD56+ immature hematolymphoid malignancy: reappraisal of blastic plasmacytoid dendritic cell and -related neoplasms. ( 28795410 )
2017
49
CD4-Negative Variant of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm With a Novel PBRM1 Mutation in an 11-Year-Old Girl. ( 28419186 )
2017
50
A Case of Blastic Plasmacytoid Dendritic Cell Neoplasm Extensively Studied by Flow Cytometry and Immunohistochemistry. ( 28409040 )
2017

Variations for Blastic Plasmacytoid Dendritic Cell

Expression for Blastic Plasmacytoid Dendritic Cell

Search GEO for disease gene expression data for Blastic Plasmacytoid Dendritic Cell.

Pathways for Blastic Plasmacytoid Dendritic Cell

GO Terms for Blastic Plasmacytoid Dendritic Cell

Cellular components related to Blastic Plasmacytoid Dendritic Cell according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.77 BRD4 CDKN1B CDKN2A MYB MYC MYD88
2 external side of plasma membrane GO:0009897 9.46 CD4 IL3RA NCAM1 PECAM1
3 protein-containing complex GO:0032991 9.1 CDKN1B MYC MYD88 NPM1 NR3C1 TCL1A

Biological processes related to Blastic Plasmacytoid Dendritic Cell according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.8 CDKN1B MYC MYD88 NPM1 TCL1A
2 cytokine-mediated signaling pathway GO:0019221 9.73 CD4 IL3RA MYC MYD88
3 positive regulation of transcription by RNA polymerase II GO:0045944 9.61 BRD4 CDKN2A MYB MYC NPM1 NR3C1
4 G1/S transition of mitotic cell cycle GO:0000082 9.54 CDKN1B CDKN2A MYC
5 negative regulation of phosphorylation GO:0042326 9.51 CDKN1B CDKN2A
6 chromatin remodeling GO:0006338 9.5 MYB MYC NPM1
7 transcription by RNA polymerase II GO:0006366 9.48 NR3C1 SUPT3H
8 response to estradiol GO:0032355 9.46 CD4 CDKN1B
9 positive regulation of transcription, DNA-templated GO:0045893 9.23 BRD4 CD4 CDKN2A MYB MYC NPM1
10 positive regulation of glial cell proliferation GO:0060252 9.19 MYB
11 positive regulation of smooth muscle cell proliferation GO:0048661 9.16 MYB MYD88
12 positive regulation of mitochondrial membrane potential GO:0010918 8.96 TCL1A

Molecular functions related to Blastic Plasmacytoid Dendritic Cell according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.86 CDKN2A MYB MYC NR3C1 SPIB SUPT3H
2 core promoter binding GO:0001047 9.16 NPM1 NR3C1
3 protein kinase binding GO:0019901 9.1 CD4 CDKN1B CDKN2A NPM1 NR3C1 TCL1A
4 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.96 CDKN1B CDKN2A

Sources for Blastic Plasmacytoid Dendritic Cell

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....